Victoria Socha

DocwireNews

Patients requiring red blood cell transfusions may experience reactions leading to allo-sensitization, or rarely transmit infections; thus, treatments that reduce the need for transfusion s are desirable. Researchers, led by Stephen Fishbane, MD, conducted an analysis to determine whether roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, reduced the need for red blood cell transfusions in patients with non&ndash;dialysis-dependent (NDD) and dialysis-dependent (DD) chronic kidney disease (CKD) and anemia. Results were reported at the NKF Spring Clinical Meetings online. The report was titled Roxadustat Lowers Risk of RBC Transfusion in Patients with Anemia of CKD.The analysis included data from six completed randomized phase 3 studies with up to 4-year duration. The studies included patients with stage 3-5 CKD. The studies compared roxadustat with placebo among patients with NDD CKD and roxadustat with epoetin alfa among patients with DD CKD. Individual studies assessed the risk of first red blood cell transfusion; the risk was also assessed within pooled NDD and DD populations.A total of 4277 patients with NDD CKD were included in the analysis: 2391 in the roxadustat arm and 1886 in the placebo arm. At baseline, mean hemoglobin was 9.10 g/dL in the roxadustat arm and 9.10 g/dL in the placebo arm. In the DD-CKD cohort (n=3857; 1929 roxadustat/1928 epoetin alfa), mean baseline hemoglobin was 9.63 g/dL&nbsp; in the roxadustat arm and 9.67 in the epoetin alfa arm. In the NDD-CKD cohort, roxadustat reduced the risk of red blood cell transfusion by 74% versus placebo; in the DD-CKD cohort, roxadustat reduced the risk of red blood cell transfusion by 18% versus epoetin alfa.In conclusion, the researchers said, &ldquo;Roxadustat markedly and significantly reduced the risk of red blood cell transfusion during anemia treatment compared with placebo in NDD CKD and, versus epoetin alfa in DD CKD in the pooled patient populations.&rdquo;Source: Fishbane S, Provenzano R, Rastoki A, et al. Roxadustat lowers risk of RBC transfusion in patients with anemia of CKD. Abstract of a presentation at the National Kidney Foundation 2020 Spring Clinical Meetings; abstract #186.

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

Latest News

Risk of Red Blood Cell Transfusion Lowered with Roxadustat in Patients with CKD Anemia

Chronic Kidney Disease

Patients requiring red blood cell transfusions may experience reactions leading to allo-sensitization, or rarely transmit infections; thus, treatments that reduce the need for ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe